Tag: UDCA

Primary Biliary Cholangitis Treatment: What Works in 2026

Primary Biliary Cholangitis Treatment: What Works in 2026
Posted by: Alan Burity Vitulo in: Health and Medicine
27 Feb | 11:10 AM | 0

As of 2026, PBC treatment has shifted dramatically with the withdrawal of Ocaliva and the rise of seladelpar and elafibranor. Learn how UDCA remains first-line, what the new options do, and how to navigate treatment decisions.

read more
Go!

recent posts

Primary Biliary Cholangitis Treatment: What Works in 2026
Primary Biliary Cholangitis Treatment: What Works in 2026

As of 2026, PBC treatment has shifted dramatically with the withdrawal of Ocaliva and the rise of seladelpar and elafibranor. Learn how UDCA remains first-line, what the new options do, and how to navigate treatment decisions.

Published ON: 27 Feb
Irritable Bowel Syndrome: Understanding Symptoms, Triggers, and Real Medication Options
Irritable Bowel Syndrome: Understanding Symptoms, Triggers, and Real Medication Options

IBS causes recurring abdominal pain, bloating, and bowel changes. Learn the real symptoms, common triggers like food and stress, and proven medication options for IBS-D, IBS-C, and mixed types - plus non-drug strategies that work.

Published ON: 2 Feb
How DTC Advertising Shapes Patient Perceptions of Generic Medications
How DTC Advertising Shapes Patient Perceptions of Generic Medications

DTC prescription drug ads in the U.S. drive higher demand for branded medications, often overshadowing equally effective generics. Research shows ads increase prescriptions but also lead to inappropriate requests and higher costs. Learn how advertising influences patient decisions and healthcare outcomes.

Published ON: 6 Feb
Subclinical Hypothyroidism: When to Treat Elevated TSH
Subclinical Hypothyroidism: When to Treat Elevated TSH

Subclinical hypothyroidism means elevated TSH with normal thyroid hormone levels. Should you treat it? The answer depends on your age, antibodies, symptoms, and risk factors-not just the lab number.

Published ON: 3 Feb
C. difficile Colitis: Antibiotic Risks and Fecal Transplant Explained
C. difficile Colitis: Antibiotic Risks and Fecal Transplant Explained

C. difficile colitis is a serious infection triggered by antibiotics, causing severe diarrhea and recurring illness. Fecal transplants offer a 90% cure rate for recurrent cases, outperforming traditional antibiotics. Learn which drugs carry the highest risk and how microbiome therapy is changing treatment.

Published ON: 19 Feb

categories

archives

tags

dietary supplement medication safety treatment online pharmacy health benefits benefits online pharmacy Australia generic drugs role drug interactions calcium carbonate immune system sexual health potential treatment pain relief prevention heart health buspirone chronic pain exercise